Taysha Gene Therapies, Inc. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Taysha Gene Therapies, Inc. (TSHA) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $7.80 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Notes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2024-03-19
- Taysha Gene Therapies, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $7.80M.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2023-12-31 | $7.80M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |